References
Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. British Medical Journal 1: 1097–1099, 1978
Ashburn PE. Polypharmacy in skilled nursing facilities. Annals of Internal Medicine 118: 649–650, 1993
Anderson M, Schou JS. Safety implications of the over-the-counter availability of H2-antagonists. Drug Safety 8: 179–185, 1993
Banfield C, O’Reilly R, Chan E, Rowland M. Phenylbutazone interaction in man: further stereochemical and metabolic considerations. British Journal of Clinical Pharmacology 16: 669–675, 1983
Blum RA, D’Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Annals of Internal Medicine 114: 755–757, 1991
Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clinical Pharmacokinetics 18: 220–239, 1990
Cadieux RJ. Drug interactions in the elderly. Postgraduate Medicine 86: 179–186, 1989
Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361: 650–654, 1993
Cranz H. The future of self-medication. Drugs Made in Germany 30: 14–16, 1987
Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clinical Pharmacokinetics 17: 236–263, 1989
Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Annals of Internal Medicine 100: 258–268, 1984
Gilbertson WE. The FDA’s OTC drug review. In Feldmann et al. (Eds) Handbook of nonprescription drugs, 9th ed., pp. 25–40, American Pharmaceutical Association, Washington, 1990
Greenblatt RM, Hollander H, McMaster JR, Henke CJ. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. Journal of Acquired Immune Deficiency Syndromes 4: 136–143, 1991
Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics 52: 231–238, 1992
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. Journal of the American Medical Association 269: 1513–1518, 1993
Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics 51: 18–23, 1992
Inaba T, Jurima M, Mahon WA, Kalow W In vitro studies of two isozymes of human liver cytochrome P450. Drug Metabolism and Disposition 13: 443–448, 1985
Johnston GD, Finch MB, McNeill JA, Shanks RG. A comparison of the cardiovascular effects of (+)-sotalol and (±)-sotalol following intravenous administration in normal volunteers. British Journal of Clinical Pharmacology 20: 507–510, 1985
Jones JK. Assessing potential risk of drugs: the elusive target. Annals of Internal Medicine 117: 691–692, 1992
Kassier WJ, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Archives of Internal Medicine 151: 2281–2288, 1991
Kroenke K, Pinholt EM. Reducing polypharmacy in the elderly: a controlled trial of physician feedback. Journal of the American Geriatrics Society 38: 31–36, 1990
Lake KD, Nolen JG, Slaker RA, Reutzel TJ, Milfred SK, et al. Over-the-counter medications in cardiac transplant recipients: guidelines for use. DICP: Annals of Pharmacotherapy 26: 1566–1575, 1992
Lindeman RD. Changes in renal function with aging: implications for treatment. Drugs and Aging 2: 423–431, 1992
Lowenthal DT. Drug therapy in the elderly: special considerations. Geriatrics 42: 77–82, 1987
MacLennan WJ. The ageing society. British Journal of Hospital Medicine 39: 112–118, 1988
McGinnis LS. Alternative therapies, 1990. Cancer 67 (6S): 1788–1792, 1991
MacNeil S, Hansen-Nortey E, Paschalis C, Eastwood PR, Jenner FA. Diuretics during lithium therapy. Lancet 1: 1295–1296, 1975
May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clinical Pharmacology and Therapeutics 22: 322–328, 1977
Osterlind PO, Bucht G. Drug consumption during the last decade among persons born in 1902 in Umea, Sweden: a longitudinal population study. Drugs and Aging 1: 477–486, 1991
Ostrom JR, Hammarlund ER, Christensen DB, Plein JB, Kethley AJ. Medication usage in an elderly population. Medical Care 23: 157–164, 1985
Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. Journal of the American Medical Association 269: 1550–1552, 1993
Schmucker DL. Aging and drug disposition: an update. Pharmacological Reviews 37: 133–147, 1985
Soumerai SB, Avorn J. Predictors of physician prescribing change in an educational experiment to improve medication use. Medical Care 25: 210–221, 1987
Steinberg JR. Prescription drug impairment in the elderly. Drug Therapy 20 (August Suppl.): 83–98, 1990
Stewart RB, Yedinak KC, Ware MR. Polypharmacy in psychiatry: three case studies and methods for prevention. DICP: Annals of Pharmacotherapy 26: 529–532, 1992
Sullivan AM. Jumping over the counter: Rx to OTC switch. Pharmacy Update 1: 1–13, 1990
Vestal RE. Aging and determinants in hepatic drug clearance. Hepatology 9: 331–334, 1989
Weisler JC. Tuberculosis: immunopathogenesis and therapy. American Journal of the Medical Sciences 305: 52–65, 1993
Zhou HH, Anthony LB, Wood AJJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. British Journal of Clinical Pharmacology 30: 471–475, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Honig, P.K., Cantilena, L.R. Polypharmacy. Clin. Pharmacokinet. 26, 85–90 (1994). https://doi.org/10.2165/00003088-199426020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199426020-00001